879 research outputs found
C.B. Biezeno (March 2, 1888 - September 5, 1975)
No full textObituary of prof. C.B. Biezeno, written by his former PhD candidate and his later colleague prof. W.T. Koiter.Mechanical, Maritime and Materials Engineerin
Rede uitgesproken op 17 september 1956 ter gelegenheid van de erepromotie van Dr. Th. von Karman door de promotor Dr. C.B. Biezeno
No full textRede uitgesproken door prof. C.B. Biezeno ter gelegenheid van de erepromotie aan de TH Delft van dr. Theodore von Karman.Precision and Microsystems EngineeringMechanical, Maritime and Materials Engineerin
Complex care strategies in patients undergoing combined chemo and targeted therapy
No full textExperimentele farmacotherapi
Biezeno en de mechanica - Herdenkingsdag 14 mei 1976.
No full textPresentations at a symposium commemorating the death of prof.dr.ir. C.B. Biezeno on 5 September 1975. Presentations by prof. A. van der Neut, prof. R.G. Boiten, prof. W.T. Koiter, prof. J.P. den Hartog, and prof. J.F. Besseling.Mechanical, Maritime and Materials Engineerin
De beteekenis der Wiskunde als Hulpwetenschap der Toegepaste Mechanica. Rede, uitgesproken bij de aanvaarding van het Ambt van Hoogleraar in de Toegepaste Mechanica aan de Technische Hoogeschool te Delft, den 30en September 1914.
No full textIntreerede van prof.ir. C.B. Biezeno.Mechanical, Maritime and Materials Engineerin
Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: A structured literature review
No full textBackgroundOral adverse events (OAEs) associated with multitargeted tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin inhibitors (mTORIs) are underestimated but frequent and novel presentations of mucosal manifestations. Because optimal antitumor activity requires maintaining the optimal dose, it is essential to avoid unintended treatment delays or interruptions.MethodsWe review the reported prevalence and appearance of OAEs with TKIs and mTORIs and the current oral assessment tools commonly used in clinical trials. We discuss the correlations between OAEs and hand-foot skin reaction (HFSR) and rash.ResultsThe reported prevalence of oral mucositis/stomatitis of any grade is 4% for pazopanib, 28% for sorafenib, 38% for sunitinib, 41% for temsirolimus, and 44% for everolimus. Oral lesions associated with these agents have been reported to more closely resemble aphthous stomatitis than OM caused by conventional agents. In addition, these agents may result in symptoms such as oral mucosal pain, dysgeusia, and dysphagia, in the absence of clinical lesions. Because of these factors, OAEs secondary to targeted agents may be underreported. In addition, a correlation between OAEs and HFSR was identified.ConclusionsOAEs caused by TKIs and mTORIs may represent dose-limiting toxicities, especially considering the fact that even low grades of OAEs may be troubling to the patient. We discuss how these novel AEs can be assessed because current mucositis assessment tools have limitations. Prospective studies investigating the pathogenesis, risk factors, and management of OAEs are needed in order to minimize the impact on patient's health-related quality of life.Christine B. Boers-Doets, Joel B. Epstein, Judith E. Raber-Durlacher, Jan Ouwerkerk, Richard M. Logan, Jan A. Brakenhoff, Mario E. Lacouture, Hans Gelderblo
Afscheidscollege van Prof. Dr Ir C.B. Biezeno
No full textMechanical, Maritime and Materials Engineerin
John and Pete Johson with C.B. Olson
No full textPhotograph - Three men holding up furs with numerous furs hanging on a fence in the background, Soto Landing, Alberta. A note on back reads: John and Pete Johnson and C.B. Olson nearly cleaned a pack of wolves south side of Marten Mountain at Wasp Cree
- …
